WallStreetZenWallStreetZen

NASDAQ: COGT
Cogent Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for COGT

Based on 5 analysts offering 12 month price targets for Cogent Biosciences Inc

Min Forecast
$52.00+57.24%
Avg Forecast
$56.80+71.76%
Max Forecast
$67.00+102.6%

Should I buy or sell COGT stock?

Based on 5 analysts offering ratings for Cogent Biosciences Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although COGT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates COGT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their COGT stock forecasts and price targets.

COGT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-29
lockedlocked$00.00+00.00%2026-05-06
lockedlocked$00.00+00.00%2026-03-16
lockedlocked$00.00+00.00%2026-02-18
lockedlocked$00.00+00.00%2025-12-19

1 of 1

Forecast return on equity

Is COGT forecast to generate an efficient return?

Company
56.73%
Industry
96.54%
Market
175.71%
COGT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is COGT forecast to generate an efficient return on assets?

Company
38.18%
Industry
27.96%
COGT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

COGT earnings per share forecast

What is COGT's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$2.31
Avg 2 year Forecast
-$0.83
Avg 3 year Forecast
$0.49

COGT revenue forecast

What is COGT's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$11.6M
Avg 2 year Forecast
$352.2M
Avg 3 year Forecast
$699.8M

COGT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
COGT$33.07$56.80+71.76%Strong Buy
SRRK$45.56$57.89+27.06%Strong Buy
BLTE$138.19$215.40+55.87%Strong Buy
CGON$60.28$84.83+40.73%Strong Buy
LQDA$68.01$56.67-16.68%Buy
View Top Biotech Stocks

Cogent Biosciences Stock Forecast FAQ

Is Cogent Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: COGT) stock is to Strong Buy COGT stock.

Out of 5 analysts, 3 (60%) are recommending COGT as a Strong Buy, 2 (40%) are recommending COGT as a Buy, 0 (0%) are recommending COGT as a Hold, 0 (0%) are recommending COGT as a Sell, and 0 (0%) are recommending COGT as a Strong Sell.

If you're new to stock investing, here's how to buy Cogent Biosciences stock.

What is COGT's earnings growth forecast for 2026-2028?

(NASDAQ: COGT) Cogent Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.54%.

Cogent Biosciences's earnings in 2026 is -$354,303,000.On average, 14 Wall Street analysts forecast COGT's earnings for 2026 to be -$394,021,617, with the lowest COGT earnings forecast at -$452,116,739, and the highest COGT earnings forecast at -$296,028,817. On average, 13 Wall Street analysts forecast COGT's earnings for 2027 to be -$141,957,138, with the lowest COGT earnings forecast at -$378,438,455, and the highest COGT earnings forecast at $231,440,711.

In 2028, COGT is forecast to generate $84,049,971 in earnings, with the lowest earnings forecast at -$53,584,206 and the highest earnings forecast at $357,028,694.

What is COGT's revenue growth forecast for 2026-2028?

(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.84%.

Cogent Biosciences's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast COGT's revenue for 2026 to be $1,978,651,486, with the lowest COGT revenue forecast at $0, and the highest COGT revenue forecast at $5,400,283,266. On average, 13 Wall Street analysts forecast COGT's revenue for 2027 to be $60,176,293,649, with the lowest COGT revenue forecast at $17,917,218,899, and the highest COGT revenue forecast at $141,861,451,641.

In 2028, COGT is forecast to generate $119,576,846,559 in revenue, with the lowest revenue forecast at $42,197,562,268 and the highest revenue forecast at $165,130,256,426.

What is COGT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: COGT) forecast ROA is 38.18%, which is higher than the forecast US Biotechnology industry average of 27.96%.

What is COGT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year COGT price target, the average COGT price target is $56.80, with the highest COGT stock price forecast at $67.00 and the lowest COGT stock price forecast at $52.00.

On average, Wall Street analysts predict that Cogent Biosciences's share price could reach $56.80 by May 29, 2027. The average Cogent Biosciences stock price prediction forecasts a potential upside of 71.76% from the current COGT share price of $33.07.

What is COGT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: COGT) Cogent Biosciences's current Earnings Per Share (EPS) is -$2.17. On average, analysts forecast that COGT's EPS will be -$2.31 for 2026, with the lowest EPS forecast at -$2.65, and the highest EPS forecast at -$1.73. On average, analysts forecast that COGT's EPS will be -$0.83 for 2027, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at $1.35. In 2028, COGT's EPS is forecast to hit $0.49 (min: -$0.31, max: $2.09).

What is COGT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: COGT) forecast ROE is 56.73%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.